-transparent.png){kind=logo}
We evaluated four commercially available 125I-digoxin radioimmunoassay kits with regard to their ability to cross react with the digoxin metabolite dehydrodigoxin. We prepared dihydrodigoxin serum samples in digoxin-free serum over the concentration range 0.4 to 5.0 microgram/liter and assayed them with each kit according to the manufacturer's instructions. The metabolite was able to displace the 125I-labeled digoxin derivative from the antibody supplied with all four kits. However, the extent of the cross reactivity depended on the kit, ranging from essentially zero to a high degree of interference. Dihydrodigoxin is the only metabolite of digoxin to have been quantitiated in human serum, and may comprise up to 30% of total glycosides. Over the clinical and therapeutic range of serum digoxin concentrations, enough dihydrodigoxin can be produced to interfere in the determination of serum digoxin concentrations by this method. We suggest that laboratories evaluate their specific kit with regard to cross reactivity to this metabolite.
W G Kramer, and
N L Kinnear, and
H K Morgan
December 1982,
Clinical chemistry,
W G Kramer, and
N L Kinnear, and
H K Morgan
August 1976,
Chest,
W G Kramer, and
N L Kinnear, and
H K Morgan
December 1975,
The American journal of cardiology,
W G Kramer, and
N L Kinnear, and
H K Morgan
June 1978,
Clinical chemistry,
W G Kramer, and
N L Kinnear, and
H K Morgan
May 1976,
Research communications in chemical pathology and pharmacology,
W G Kramer, and
N L Kinnear, and
H K Morgan
December 1995,
The Analyst,
W G Kramer, and
N L Kinnear, and
H K Morgan
May 1979,
Clinical chemistry,
W G Kramer, and
N L Kinnear, and
H K Morgan
October 1978,
Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie,
W G Kramer, and
N L Kinnear, and
H K Morgan
November 1985,
Clinical chemistry,
W G Kramer, and
N L Kinnear, and
H K Morgan
July 1975,
Clinical chemistry,
